US 7906513
Hydrazide-containing hepatitis C serine protease inhibitors
granted A61PA61P31/12
Quick answer
US patent 7906513 (Hydrazide-containing hepatitis C serine protease inhibitors) held by Enanta Pharmaceuticals, Inc. expires Mon Mar 10 2031 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Enanta Pharmaceuticals, Inc.
- Grant date
- Tue Mar 15 2011 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Mar 10 2031 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 10
- CPC classes
- A61P, A61P31/12